GILEAD SCIENCES POSTED Q2 REVENUE OF $7.80 BLN, ABOVE THE $7.40 BLN ESTIMATE, WITH AN ADJUSTED LOSS PER SHARE OF $6.75, NARROWER THAN THE EXPECTED $7.17 LOSS, AS BIKTARVY REVENUE OF $3.77 BLN AND

TRODELVY REVENUE OF $457 MLN BOTH BEAT ESTIMATES WHILE VEKLURY REVENUE OF $23 MLN MISSED THE $98.1 MLN ESTIMATE.

متن اصلی؛ ترجمهٔ فارسی ندارد